1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Alar Pharmaceuticals Inc.

Alar Pharmaceuticals Inc.

6785.TWO
Alar Pharmaceuticals Inc.TW flagTaipei Exchange
129.00
TWD
+5.00
- -
8.62BMarket Cap

Total Valuation

Alar Pharmaceuticals Inc. carries a market capitalization of 8.62B, placing it among publicly traded companies globally. Its enterprise value stands at 17.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.62B
Enterprise Value17.85B

Share Statistics

Alar Pharmaceuticals Inc. currently has 66.80M shares outstanding.

Shares Outstanding66.80M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Alar Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 1,654.76. The price-to-sales ratio is 7,318.00, and the price-to-book ratio stands at 25.76.

PE Ratio1,654.76
PS Ratio7,318.00
PB Ratio25.76
P/TBV Ratio8.38
P/FCF Ratio-119.80
P/OCF Ratio-117.79

Enterprise Valuation

EV / Sales6,485.15
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Alar Pharmaceuticals Inc. maintains a current ratio of 31.59, meaning it holds 31.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.15, indicating conservative leverage, while an interest coverage ratio of -2,071.58 demonstrates limited ability to service its debt obligations.

Current Ratio31.59
Quick Ratio30.84
Debt / Equity0.15
Debt / EBITDA-0.02
Interest Coverage-2,071.58

Financial Efficiency

Return on Equity (ROE)-9.59
Return on Assets (ROA)-3.16
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax712,000.00
Effective Tax RateN/A

Stock Price Statistics

Alar Pharmaceuticals Inc.'s stock has declined approximately -6.52174% over the past 52 weeks. The 50-day moving average sits at 126.41, while the 200-day moving average is 213.81.

Beta (5Y)N/A
52-Week Price Change-6.52174%
50-Day Moving Average126.41
200-Day Moving Average213.81
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Alar Pharmaceuticals Inc. generated 2.75M in revenue and converted that into -79.68M in net income, yielding earnings per share of -1.20. EBITDA reached -167.80M, while operating income came in at -167.80M.

Revenue2.75M
Gross Profit2.14M
Operating Income-167.80M
Pretax Income-78.97M
Net Income-79.68M
EBITDA-167.80M
EBIT-167.80M
Earnings Per Share (EPS)-1.20

Balance Sheet

Alar Pharmaceuticals Inc. holds 2.30B in cash and equivalents against 3.57M in total debt, resulting in a net debt position of -1.79B. Total book value stands at 782.18M, with working capital of 2.28B providing operational flexibility.

Cash & Cash Equivalents2.30B
Total Debt3.57M
Net Debt-1.79B
Equity (Book Value)782.18M
Book Value Per Share11.80
Working Capital2.28B

Cash Flow

Alar Pharmaceuticals Inc. produced -171.03M in operating cash flow over the past twelve months. After subtracting -2.87M in capital expenditures, free cash flow totaled -173.90M - equivalent to -2.62 per share.

Operating Cash Flow-171.03M
Capital Expenditures-2.87M
Free Cash Flow-173.90M
FCF Per Share-2.62

Margins

Alar Pharmaceuticals Inc. operates with a gross margin of 77.73, reflecting its pricing power and cost economics. The operating margin of -6,095.10 and net profit margin of -2,894.41 provide insight into operational efficiency.

Gross Margin77.73
Operating Margin-6,095.10
Pretax Margin-2,868.54
Profit Margin-2,894.41
EBITDA Margin-6,095.10

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.09
FCF Yield-0.83

Scores

Alar Pharmaceuticals Inc. posts an Altman Z-Score of 144.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score144.27